Back to top
more

Novartis (NVS)

(Delayed Data from NYSE)

$119.38 USD

119.38
1,160,974

+0.88 (0.74%)

Updated Sep 4, 2024 04:00 PM ET

After-Market: $119.37 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is a Disappointment in Store for Incyte (INCY) Q4 Earnings?

by Zacks Equity Research

Investors are looking forward to Jakafi's performance and other pipeline updates when Incyte (INCY) reports Q4 results on Feb 14.

Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on pipeline progress and updates when Tilray (TLRY) reports fourth-quarter results.

Incyte Down as FDA Extends Review Period of Jakafi for GVHD

by Zacks Equity Research

The FDA extends the review period of Incyte's (INCY) sNDA for the label expansion of Jakafi for the treatment of acute GVHD.

Ligand (LGND) Beats on Q4 Earnings & Sales, Raises '19 View

by Zacks Equity Research

Ligand (LGND) beats earnings and sales estimates for the fourth quarter of 2018 and raises 2019 guidance.

Vanda (VNDA) Q4 Earnings: What's in Store for the Stock

by Zacks Equity Research

On Vanda's (VNDA) fourth-quarter 2018 conference call, investor focus will be on the sales figure of its two marketed drugs, Hetlioz and Fanapt.

Glaxo (GSK) Beats on Q4 Earnings, to Focus on Oncology in '19

by Zacks Equity Research

Glaxo (GSK) beats earnings and sales estimates in the fourth quarter. Strong sales growth of vaccine portfolio boosts sales. However, Advair generic will severely impact the drug's U.S. sales.

Glaxo Inks Deal With Merck KGaA to Co-Develop Cancer Candidate

by Zacks Equity Research

Glaxo (GSK) signs a co-development and commercialization agreement with Germany-based Merck KGaA for the latter's next-generation immunotherapy candidate, M7824.

Roche Submits sBLA to FDA for Label Expansion of Kadcyla

by Zacks Equity Research

Roche (RHHBY) submits sBLA for Kadcyla to the FDA for adjuvant treatment of patients with HER2-positive early breast cancer with residual disease after neoadjuvant treatment.

Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

A mixed fourth-quarter for biotech bigwig Gilead as it misses on earnings but beat on revenues.

Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy

by Zacks Equity Research

Teva (TEVA) receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP), advocating a marketing approval for its new migraine medicine, Ajovy.

What's in the Cards for Glaxo (GSK) This Earnings Season?

by Zacks Equity Research

Glaxo's (GSK) Vaccines segment is likely to witness strong sales in the fourth quarter.

Mylan's Generic Version of Advair Diskus Wins FDA Approval

by Zacks Equity Research

Mylan (MYL) secures an FDA approval for the first generic version of blockbuster COPD drug, Advair Diskus.

Roche (RHHBY) 2018 Sales Up on Solid New Drugs Performance

by Zacks Equity Research

Roche's (RHHBY) performance in 2018 is driven by solid strength in new drugs, which more than offset competition from biosimilars.

Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY

by Zacks Equity Research

Pfizer (PFE), Allergan (AGN), AbbVie (ABBV) and Novartis (NVS) report Q4 results.

Novartis (NVS) Q4 Earnings Miss Estimates, Revenues Up Y/Y

by Zacks Equity Research

Novartis (NVS) misses estimates in Q4 as generic unit continues to face challenging business conditions. The outlook for 2019 didn't impress investors either.

Novartis Misses Earnings and Sales Estimates in Q4

by Zacks Equity Research

Novartis (NVS) missed estimates both for earnings and sales in the fourth quarter of 2018.

Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid

by Zacks Equity Research

Allergan (AGN) beats fourth-quarter estimates for earnings and sales with Botox being the primary sales driver. The company provides full-year guidance for 2019.

Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid

by Zacks Equity Research

Allergan (AGN) beats fourth-quarter estimates for earnings and sales with Botox being the primary sales driver. The company provides full-year guidance for 2019.

Amgen (AMGN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.

Is a Surprise in the Cards for Novartis (NVS) in Q4 Earnings?

by Zacks Equity Research

Swiss-giant Novartis (NVS) is set to report fourth-quarter earnings on Jan 30. While the pharma business should maintain growth, the generic division is expected to lag.

Alnylam & Medison Partner to Market RNAi Products in Israel

by Zacks Equity Research

Alnylam (ALNY) partners with Israel's Medison Pharma to commercialize Onpattro and other RNAi pipeline candidates under development in the former's portfolio.

Lilly Stops Lartruvo Promotion as Confirmatory Study Fails

by Zacks Equity Research

Eli Lilly's (LLY) Lartruvo combo is unable to demonstrate the clinical benefit for the primary endpoint of OS rate in a phase III study related to treating patients with metastatic soft tissue sarcoma.

NVS or AZN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

NVS vs. AZN: Which Stock Is the Better Value Option?

Intrexon Signs Licensing Agreement with Next Green Wave

by Zacks Equity Research

Intrexon (XON) partners with Next Green Wave Holdings to utilize Intrexon's Botticelli next-generation plant propagation platform.

Tilray Teams Up With Authentic Brands, Stock Down on Sell-Off

by Zacks Equity Research

Tilray (TLRY) signs a marketing agreement with Authentic Brands Group to sell consumer cannabis products.